TRT at Leger: what the science says about testosterone therapy

What did @legertreatments actually say?

Richard, an Advanced Nurse Practitioner at Leger, walked through a two-stage diagnostic pathway for TRT. First, a finger-prick blood test screens testosterone levels. If results come back low, patients move to a more thorough blood panel and a consultation with a doctor who decides whether "symptoms and levels are low enough to warrant treatment." Ongoing monitoring then happens at one, three, six, and twelve months in year one, then every six months after stabilisation.

This is a process video, not a bold medical claim video. Richard does not promise outcomes, does not quote specific testosterone thresholds, and does not mention specific drugs or doses. That restraint is worth acknowledging upfront. What he does say opens up several legitimate questions about the adequacy of finger-prick screening and the diagnostic standards implied.

Does the science back this up?

Mostly, yes. The monitoring schedule Richard describes is broadly consistent with published clinical guidelines. The diagnostic caution, requiring both low levels and symptomatic presentation, reflects current evidence. The finger-prick screening step, however, is where things get more complicated.

The American Urological Association (AUA) 2018 guidelines and the Endocrine Society 2018 Clinical Practice Guideline both state that hypogonadism diagnosis requires at least two separate morning venous serum testosterone measurements, not a single capillary sample. Finger-prick tests measuring testosterone via dried blood spot (DBS) have been studied. A 2019 paper by Kushnir et al. in the Journal of Steroid Biochemistry and Molecular Biology found DBS methods can correlate with serum for some androgens but raised concerns about accuracy at low testosterone concentrations, which is precisely the clinically relevant range here. A 2021 review in Endocrine Practice also cautioned that DBS testosterone lacks the validation depth of venous serum assays for diagnostic use.

The follow-up "more in-depth blood test" at stage two partially addresses this, but the video implies the finger-prick result alone determines whether you proceed, which is an oversimplification of the diagnostic standard.

What did they get wrong (or right)?

Right: The two-step process that layers symptom assessment on top of bloodwork is correct clinical practice. Testosterone levels alone do not confirm hypogonadism. The Endocrine Society explicitly requires both biochemical and clinical evidence. Richard saying doctors look at "symptoms and levels" together is accurate, and it is the kind of nuance that often gets dropped in direct-to-consumer TRT marketing.

Right: The monitoring cadence of one, three, six, and twelve months in year one is consistent with what the British Society for Sexual Medicine (BSSM) 2017 guidelines recommend for men starting TRT. Monitoring haematocrit, prostate-specific antigen, and testosterone levels at those intervals is standard of care.

Questionable: Framing the finger-prick test as a screening entry point is not inherently wrong, but presenting it as step one of a clinical diagnostic pathway, without clearly flagging it as a screening tool only, risks patients treating that result as diagnostic. It is not. If the screen comes back borderline, the absence of a morning venous confirmatory draw at stage one is a gap.

Wrong-ish: "Take back control and feel like yourself again" is standard telehealth marketing language. It sets an expectation that TRT reliably restores subjective wellbeing. A 2020 meta-analysis by Corona et al. in the Journal of Sexual Medicine found TRT improved sexual function and some mood outcomes in hypogonadal men, but effects on energy and quality of life were inconsistent and study-dependent. The framing oversells certainty.

What should you actually know?

If you are considering TRT, the diagnostic process matters more than most content in this space acknowledges. A real diagnosis of hypogonadism requires two morning venous blood draws on separate occasions, ideally before 10am when testosterone peaks, plus a clinical symptom assessment. One finger-prick test, or one blood test of any kind, does not meet that standard alone.

Second-stage markers worth asking about include LH, FSH, SHBG, prolactin, and haematocrit. These differentiate primary from secondary hypogonadism and flag contraindications. If a clinic's "more in-depth blood test" does not include these, ask why.

Monitoring at the intervals Richard describes is genuinely important, not just administrative. Testosterone therapy raises red blood cell production, which increases clotting risk if haematocrit climbs above around 54 percent. The FDA updated its testosterone product labelling in 2015 to require cardiovascular risk warnings. Clinics that skip or delay monitoring are cutting a corner that has real physiological consequences.

• Finger-prick DBS testosterone testing is a screening tool, not a standalone diagnostic method.
• Legitimate hypogonadism diagnosis requires two separate morning venous serum testosterone measurements per AUA and Endocrine Society guidelines.
• Symptom-plus-biochemistry assessment is the correct standard, and Leger's process description does reflect this.
• Year-one monitoring at one, three, six, and twelve months aligns with BSSM 2017 guidelines.
• Claims that TRT will make you "feel like yourself again" outrun what the evidence consistently shows for quality-of-life outcomes.